Mild Cognitive Impairment Clinical Trial
Official title:
Spanish Translation and Cultural Adaptation of the Memory Support System
NCT number | NCT03933085 |
Other study ID # | 18-008125 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 6, 2019 |
Est. completion date | July 31, 2021 |
Verified date | October 2021 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study seeks to translate a proven cognitive treatment for Spanish-speaking Hispanics with subjective memory/cognitive complaints or a diagnosis of mild cognitive impairment (MCI) and their care partners. MCI causes cognitive changes that are noticed by the individual or others. These changes do not significantly interfere with independence. MCI also increases the risk of developing Alzheimer's or another dementia, particularly in Hispanics/Latinos. There is no medication that improves cognition or delays MCI. However, providing cognitive treatment can alleviate the effects of MCI. Only a few cognitive interventions have been proven effective in the U.S., but none has been adapted to the Spanish-speaking Hispanic community. Our proposed cognitive treatment uses effective strategies (e.g., calendar and notetaking) to compensate for memory loss. The investigators will first follow international guidelines to ensure proper translation of our treatment into Spanish. Then, the investigators will pilot test our translated intervention in 20 Spanish-speaking Hispanic participants with subjective memory/cognitive complaints or a diagnosis of MCI and their care partners (40 participants total). The investigators will also assess the degree to which participants follow medical advice; their beliefs in their ability to succeed in and do daily activities, including managing medications; their feelings and potential burden associated with caregiving before and after the treatment as well as 8 weeks later. Results will allow the investigators to determine whether our treatment was effective and to calculate the number of participants required for larger studies. Overall, the study represents an important step to respond to the needs of the Hispanic community.
Status | Completed |
Enrollment | 40 |
Est. completion date | July 31, 2021 |
Est. primary completion date | February 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Subjective memory/cognitive complaints or a diagnosis of single or multi-domain MCI - Global score of =0.5 on the Clinical Dementia Rating (CDR) - Scores of =4 on items six to nine on the Linguistic History Form (CLS) and scores of =6 on items on the Functional Assessment Scale (FAS), when applicable, from the Spanish language Uniformed Data Set (UDS) from the National Alzheimer's Coordinating Center's (NACC); - A score of =115 on the Spanish Translation of the Dementia Rating Scale-Second edition (ST-DRS-2); - Having contact with a cognitively normal care partner screened with the Mini Mental Status Examination (MMSE =24) at least twice a week; and - Either not taking or stable on nootropic(s) for at least 3 months. Exclusion Criteria: - Visual/hearing impairment and/or history of reading or written inability/disability sufficient to interfere with MSS training; and/or - Inclusion in another clinical trial that would exclude participation; subject will be considered for participation at the end of such a trial or as appropriate. |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Jacksonville | Florida |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Intervention evaluation by participants and support partners | To evaluate intervention at the end of MSS training, each dyad will undergo a qualitative semi-structured interview by the therapist about the training process itself, seeking suggestions for improving the MSS, teaching curriculum, and intervention logistics. | 2-month follow-up | |
Primary | Change from Baseline Memory Support System (MSS) adherence at 2 weeks after intervention start and at 2-month follow-up | To assess MSS adherence (i.e., how well a participant with subjective memory/cognitive complaints or a diagnosis of MCI utilizes all the MSS sections), the therapist will rate each participant based upon four criteria (=7/10 scores considered compliant) for 2 days randomly selected. | 2 weeks after intervention start and 2-month follow-up | |
Secondary | Change from Baseline Memory functional ability at 2 weeks after intervention start and at 2-month follow-up | To assess memory functional ability, care partners will complete a modified version of the Memory Subscale of the Everyday Cognition (E-Cog) at all assessment points. The E-Cog scores range from 8 to 32, where lower scores represent better memory functional ability. | 2 weeks after intervention start and 2-month follow-up | |
Secondary | Change from Baseline Self-efficacy at 2 weeks after intervention start and at 2-month follow-up | To assess self-efficacy, participants with subjective memory/cognitive complaints or a diagnosis of MCI will complete a modified version of specific subscales the Self-Efficacy in Memory scale (SEM) (Do Chores, Social/Recreational Activities, and Manage Disease in General) of the Chronic Disease Self-Efficacy Scales at all assessment points. The SEM scores range from 9 to 90, where higher scores represent better self-efficacy. | 2 weeks after intervention start and 2-month follow-up | |
Secondary | Change from Baseline Mood at 2 weeks after intervention start and at 2-month follow-up | To assess mood, participants with subjective memory/cognitive complaints or a diagnosis of MCI and care partners will complete the Center for Epidemiological Studies Depression Scale (CES-D) at all assessment points. The CES-D scores range from 0-60, where higher scores represent more symptoms of depression. | 2 weeks after intervention start and 2-month follow-up | |
Secondary | Change from Baseline Anxiety at 2 weeks after intervention start and at 2-month follow-up | To assess anxiety, participants with subjective memory/cognitive complaints or a diagnosis of MCI and care partners will complete the Anxiety Inventory Form from the State-Trait Anxiety Inventory by the Resources for Enhancing Alzheimer's Caregiver Health project (REACH) at all assessment points. The REACH scores range from 10-40, where higher scores represent more symptoms of anxiety. | 2 weeks after intervention start and 2-month follow-up | |
Secondary | Change from Baseline Quality of Life at 2 weeks after intervention start and at 2-month follow-up | To assess quality of life, participants with subjective memory/cognitive complaints or a diagnosis of MCI and care partners will complete the Quality of Life in Alzheimer's Disease measure (QoL-AD) at all assessment points. The QoL-AD scores range from 13-52, where higher scores represent better quality of life. | 2 weeks after intervention start and 2-month follow-up | |
Secondary | Change from Baseline General Functional Ability at 2 weeks after intervention start and at 2-month follow-up | To assess general functional ability, care partners will complete the Functional Assessment Scale (FAS) | 2 weeks after intervention start and 2-month follow-up | |
Secondary | Change from Baseline Caregiver Burden at 2 weeks after intervention start and at 2-month follow-up | To assess caregiver burden, care partners will complete the Caregiver Burden Interview-Short Form (CBI-SF) at all assessment points. The CBI-SF scores range from 0-48, where higher scores represent more care giver burden. | 2 weeks after intervention start and 2-month follow-up | |
Secondary | Change from Baseline Medication Management Skills at 2 weeks after intervention start and at 2-month follow-up | To assess medication management skills, participants with subjective memory/cognitive complaints or a diagnosis of MCI will complete the Pillbox Test (PT) at all assessment points (=5 errors considered failure). | 2 weeks after intervention start and 2-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |